Analysts Issue Forecasts for Nanobiotix FY2026 Earnings

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) – Research analysts at HC Wainwright dropped their FY2026 earnings estimates for Nanobiotix in a report issued on Monday, March 30th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $1.05 for the year, down from their prior forecast of $1.06. The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Nanobiotix’s FY2028 earnings at $0.58 EPS and FY2030 earnings at $2.33 EPS.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $3.42 million during the quarter.

Several other research analysts have also issued reports on NBTX. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Finally, Guggenheim increased their target price on shares of Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Nanobiotix presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Nanobiotix Stock Up 10.4%

Shares of NBTX stock opened at $34.07 on Thursday. The stock’s fifty day simple moving average is $27.90 and its 200 day simple moving average is $23.20. Nanobiotix has a one year low of $2.99 and a one year high of $41.89.

Hedge Funds Weigh In On Nanobiotix

Institutional investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new position in Nanobiotix in the fourth quarter worth $220,000. Millennium Management LLC acquired a new stake in shares of Nanobiotix in the fourth quarter valued at $390,000. Royal Bank of Canada increased its stake in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares in the last quarter. Finally, Optiver Holding B.V. bought a new position in shares of Nanobiotix in the third quarter valued at about $101,000. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.